Sunitinib Improves Progression-Free Survival in Patients With Advanced Pancreatic Islet Cell Tumors

Publication
Article
OncologyONCOLOGY Vol 23 No 8
Volume 23
Issue 8

Pfizer announced results from a randomized phase III trial of sunitinib malate (Sutent) in patients with advanced pancreatic islet cell (neuroendocrine) tumors

Pfizer announced results from a randomized phase III trial of sunitinib malate (Sutent) in patients with advanced pancreatic islet cell (neuroendocrine) tumors. Study findings demonstrated that median progression-free survival was 11.1 months in patients treated with sunitinib compared to 5.5 months in patients treated with placebo. Researchers presented these data at the 11th World Congress on Gastrointestinal Cancer in Barcelona, Spain.

The independent Data Monitoring Committee recommended halting the trial earlier this year because sunitinib showed significant benefit and the study had met its primary endpoint. Full analysis of the data is ongoing.

Articles in this issue
Resolving Confusion: The New Realities of Mantle Cell Lymphoma
Something Old, Something New: Options for Treating Relapsed Mantle Cell Lymphoma
Supraclavicular Extraskeletal Myxoid Chondrosarcoma Presenting With a Sensorimotor Polyneuropathy Associated With Anti-Hu Antibodies
Supraclavicular Extraskeletal Myxoid Chondrosarcoma Presenting With a Sensorimotor Polyneuropathy Associated With Anti-Hu Antibodies
Reishi Mushroom
Reishi Mushroom
Unraveling the Mystery of a Supraclavicular Mass
Management of Relapsed Mantle Cell Lymphoma: Still a Treatment Challenge
Sunitinib Improves Progression-Free Survival in Patients With Advanced Pancreatic Islet Cell Tumors
Phase III Trial Initiated for BLP25 Liposome Vaccine in Breast Cancer Patients
US Oncology Launches Oncology-Specific EHR
Effective Local Therapy and Long-Term Survival in Breast Cancer
Local Therapy Matters
Deemphasize Dogma: Consider the Local Control–Overall Survival Link
Romiplostim for the Treatment of Chronic Immune (Idiopathic) Thrombocytopenic Purpura
The Road to Romiplostim Approval and Beyond
The REMS Publication Paradox
Recent Videos
Experts from Vanderbilt University Medical Center emphasize gathering a second opinion to determine if a tumor is resectable in patients with pancreatic cancer.
Experts from Vanderbilt University Medical Center discuss the use of intraoperative radiation therapy in a 64-year-old patient with pancreatic cancer.
Investigators are assessing the use of IORT in patients with borderline resectable or unresectable pancreatic cancer as part of the phase 2 PACER trial.
Kamran Idrees, MD, MSCI, MMHC, FACS, discusses how factors such as vessel involvement can influence the decision to proceed with surgical therapy.
Milad Baradaran, PhD, DABR, outlines the design of Mobetron as an option for administering intraoperative radiation therapy in pancreatic cancer care.
Intraoperative radiation therapy may allow surgical and radiation oncologists to collaboratively visualize at-risk areas in patients with cancer.
Positive margin rates have not appeared to improve for patients with cancer undergoing surgical care based on several prior studies.
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Teresa Macarulla, MD, PhD, and Cindy Neuzillet, MD, PhD, experts on NRG1 fusion-positive malignancies
Related Content
Study data show that no patient with a response required opioids after a 24-hour post-procedure follow-up.

Transvascular Approach May Reduce Pain, Improve QOL in Pancreatic Cancer

Russ Conroy
November 2nd 2024
Article

Study data show that no patient with a response required opioids after a 24-hour post-procedure follow-up.

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.

Advancing Pancreatic Cancer Care Through Intraoperative Radiation Therapy

Kamran Idrees, MD, MSCI, MMHC, FACS ;Natalie A. Lockney, MD;Milad Baradaran, PhD, DABR
August 5th 2024
Podcast

Experts from Vanderbilt Medical Center review mechanisms, supporting data, and patient cases associated with the use of IORT in pancreatic cancer.

Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

Mitigating Adverse Effects Following GPRC5DTargeted Therapy in Multiple Myeloma

ONCOLOGY Staff
October 27th 2024
Article

A panel of experts in multiple myeloma discussed strategies for monitoring and mitigating adverse effects associated with GPRC5D-targeting bispecific agents.

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Diane M. Simeone, MD “Thrilled” To Be UCSD Moores Cancer Center Director

Diane Simeone, MD
February 26th 2024
Podcast

Diane M. Simeone, MD highlights the importance of multidisciplinary care, surgical practices, and early detection in pancreatic cancer care.

Assessing Immunotherapy Options for PD-L1 NSCLC

Assessing Immunotherapy Options for PD-L1 NSCLC

ONCOLOGY Staff
October 25th 2024
Article

A panel of experts focused on the use of dual immunotherapy options for patients with metastatic NSCLC without driver mutations.

City of Hope Claims Victory After Updated CROWN Presentation Data in NSCLC

City of Hope Claims Victory After Updated CROWN Presentation Data in NSCLC

ONCOLOGY Staff
October 24th 2024
Article

Experts in non–small cell lung cancer met to debate the latest advances and treatment options and the hottest topics in the space.